| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
136,480,000 |
| Market
Cap: |
3.66(B) |
| Last
Volume: |
503,160 |
Avg
Vol: |
501,799 |
| 52
Week Range: |
$26.23 - $39.94 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Related Products |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
| |
NASDAQ COMPOSITE |
|
S&P 400 MIDCAP |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Perrigo is a provider of over-the-counter health and wellness solutions that can be self-managed. Co.'s segments are as follows: Consumer Self-Care Americas, which is focused primarily on the sale of self-care products in categories including upper respiratory, pain and sleep-aids, digestive health, nutrition, vitamins, minerals and supplements; Consumer Self-Care International, which develops, manufactures, markets, and distributes European consumer self-care brands in the upper respiratory, pain and sleep-aids, digestive health, vitamins, minerals and supplements; and Prescription Pharmaceuticals, which develops, manufactures, and markets a portfolio of generic prescription drugs.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-03-17 |
2023-12-15 |
2023-06-16 |
2022-06-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Papa Joseph C |
President and CEOChairman |
• • – |
2010-08-19 |
4 |
A |
$0.00 |
$0 |
D/D |
54,321 |
134,952 |
|
- |
|
| Yu Louis |
Senior VP Global Quality |
• – – |
2010-08-19 |
4 |
D |
$58.82 |
$78,701 |
D/D |
(1,338) |
3,871 |
|
- |
|
| Yu Louis |
Senior VP Global Quality |
• – – |
2010-08-19 |
4 |
A |
$0.00 |
$0 |
D/D |
4,344 |
5,209 |
|
- |
|
| Lebel Refael |
EVP & GM Perrigo Israel |
• – – |
2010-08-19 |
4 |
A |
$0.00 |
$0 |
D/D |
10,865 |
12,386 |
|
- |
|
| Stewart Michael Robert |
Sr. VP Global Human Resources |
• – – |
2010-05-27 |
4 |
S |
$60.10 |
$360,570 |
D/D |
(6,000) |
1,526 |
|
- |
|
| Brown Judy L |
Executive VP & CFO |
• – – |
2010-05-27 |
4 |
S |
$60.14 |
$686,822 |
D/D |
(11,420) |
13,144 |
|
- |
|
| Brown Judy L |
Executive VP & CFO |
• – – |
2010-05-27 |
4 |
OE |
$20.50 |
$327,162 |
D/D |
11,420 |
24,564 |
|
- |
|
| Jandernoa Michael J |
Director |
– • – |
2010-05-13 |
5 |
GD |
$0.00 |
$0 |
I/I |
5,922 |
1,508,420 |
|
- |
|
| Kingma Todd W |
Executive VP, General Counsel |
• – – |
2010-05-13 |
4 |
GD |
$0.00 |
$0 |
D/D |
1,100 |
18,819 |
|
- |
|
| Gibbons David T |
Director |
– • – |
2010-05-12 |
4/A |
S |
$64.34 |
$4,182,035 |
D/D |
(65,000) |
40,872 |
|
- |
|
| Gibbons David T |
Director |
– • – |
2010-05-12 |
4 |
S |
$64.34 |
$41,820,350 |
D/D |
(650,000) |
40,872 |
|
- |
|
| Gibbons David T |
Director |
– • – |
2010-05-12 |
4 |
OE |
$18.18 |
$1,181,700 |
D/D |
65,000 |
105,872 |
|
- |
|
| Morris Herman Jr |
Director |
– • – |
2010-05-12 |
4 |
S |
$64.24 |
$681,800 |
D/D |
(10,613) |
14,794 |
|
- |
|
| Morris Herman Jr |
Director |
– • – |
2010-05-12 |
4 |
OE |
$6.56 |
$69,653 |
D/D |
10,613 |
25,407 |
|
- |
|
| Kingma Todd W |
Executive VP, General Counsel |
• – – |
2010-05-12 |
4 |
GA |
$0.00 |
$0 |
I/I |
200 |
175 |
|
- |
|
| Kingma Todd W |
Executive VP, General Counsel |
• – – |
2010-05-12 |
4 |
GD |
$0.00 |
$0 |
D/D |
900 |
19,919 |
|
- |
|
| Kochan Sharon |
Executive VP U.S. Generics |
• – – |
2010-05-11 |
4 |
S |
$62.74 |
$162,371 |
D/D |
(2,588) |
3,805 |
|
- |
|
| Kochan Sharon |
Executive VP U.S. Generics |
• – – |
2010-05-11 |
4 |
OE |
$35.85 |
$92,780 |
D/D |
2,588 |
6,393 |
|
- |
|
| Kingma Todd W |
Executive VP, General Counsel |
• – – |
2010-05-11 |
4 |
S |
$63.05 |
$915,287 |
D/D |
(14,518) |
20,819 |
|
- |
|
| Kingma Todd W |
Executive VP, General Counsel |
• – – |
2010-05-11 |
4 |
OE |
$15.47 |
$273,717 |
D/D |
14,518 |
35,337 |
|
- |
|
| Lebel Refael |
EVP & GM Perrigo Israel |
• – – |
2010-05-11 |
4 |
S |
$61.04 |
$1,628,650 |
D/D |
(26,062) |
1,521 |
|
- |
|
| Lebel Refael |
EVP & GM Perrigo Israel |
• – – |
2010-05-11 |
4 |
OE |
$20.50 |
$299,574 |
D/D |
11,920 |
13,441 |
|
- |
|
| Lebel Refael |
EVP & GM Perrigo Israel |
• – – |
2010-05-06 |
4 |
S |
$61.13 |
$30,565 |
D/D |
(500) |
15,663 |
|
- |
|
| Lebel Refael |
EVP & GM Perrigo Israel |
• – – |
2010-05-05 |
4 |
S |
$61.71 |
$308,558 |
D/D |
(5,000) |
16,163 |
|
- |
|
| Shah Jatin |
Sr VP & Chief Scientific Offic |
• – – |
2010-05-05 |
4 |
S |
$61.10 |
$647,618 |
D/D |
(10,600) |
3,175 |
|
- |
|
1400 Records found
|
|
Page 28 of 56 |
|
|
0.54 (1.97%) 
